Literature DB >> 25908480

Associations between the functional CD40 rs4810485 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis.

Y H Lee1, S-C Bae2, S J Choi3, J D Ji3, G G Song3.   

Abstract

OBJECTIVE: The aim of this study was to determine whether the functional CD40 rs4810485 G/T polymorphism is associated with susceptibility to rheumatoid arthritis (RA) or with susceptibility to systemic lupus erythematosus (SLE).
METHODS: A series of meta-analyses were conducted to test for association between the CD40 rs4810485 G/T polymorphism and RA or SLE.
RESULTS: A total of 21 comparisons involving 15,095 patients and 27,050 controls for RA, and 1353 patients and 2342 controls for SLE were considered. Meta-analysis showed a significant association between the CD40 rs4810485 T allele and RA in all subjects (odds ratio (OR) 0.890, 95% confidence interval (CI) 0.846-0.936, p = 5.5 × 10(-7)). After stratification by ethnicity, the CD40 T allele was found to be significantly associated with RA in Europeans (OR 0.879, 95% CI 0.848-0.901, p = 3.0 × 10(-9)). A similar pattern of association was observed between the CD40 T allele and RA when the analysis was performed using the recessive, dominant, and additive models. Meta-analysis also showed a significant association between the CD40 polymorphism and SLE in Europeans (OR for the T allele 0.715, 95% CI 0.641-0.832, p = 1.4 × 10(-6)).
CONCLUSIONS: Our meta-analyses confirm that the CD40 rs4810485 G/T polymorphism is associated with susceptibility to RA and SLE in Europeans.
© The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  CD40; Rheumatoid arthritis; polymorphism. meta-analysis; systemic lupus erythematosus

Mesh:

Substances:

Year:  2015        PMID: 25908480     DOI: 10.1177/0961203315583543

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

Review 1.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

2.  Association of CD40 polymorphisms and haplotype with risk of systemic lupus erythematosus.

Authors:  Cheng-Jiang Wu; Jing Guo; Hong-Cheng Luo; Chuan-Dong Wei; Chun-Fang Wang; Yan Lan; Ye-Sheng Wei
Journal:  Rheumatol Int       Date:  2015-08-21       Impact factor: 2.631

3.  Single nucleotide polymorphisms in the CD40 gene associate with the disease susceptibility and severity in knee osteoarthritis in the Chinese Han population: a case-control study.

Authors:  Zhen-Han Deng; Ming-Hua Sun; Yu-Sheng Li; Wei Luo; Fang-Jie Zhang; Jian Tian; Ping Wu; Wen-Feng Xiao
Journal:  BMC Musculoskelet Disord       Date:  2017-03-21       Impact factor: 2.362

4.  Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

Authors:  Sudha Visvanathan; Stefan Daniluk; Rafał Ptaszyński; Ulf Müller-Ladner; Meera Ramanujam; Bernd Rosenstock; Anastasia G Eleftheraki; Richard Vinisko; Alena Petříková; Herbert Kellner; Eva Dokoupilova; Brygida Kwiatkowska; Rieke Alten; Christian Schwabe; Patrick Baum; David Joseph; Jay S Fine; Steven J Padula; Jürgen Steffgen
Journal:  Ann Rheum Dis       Date:  2019-03-22       Impact factor: 19.103

5.  CD40 polymorphisms were associated with HCV infection susceptibility among Chinese population.

Authors:  Ting Tian; Peng Huang; Jingjing Wu; Chunhui Wang; Haozhi Fan; Yun Zhang; Rongbin Yu; Chao Wu; Xueshan Xia; Zuqiang Fu; Jun Li; Ming Yue
Journal:  BMC Infect Dis       Date:  2019-10-15       Impact factor: 3.090

6.  Association of CD40 Gene Polymorphisms With Systemic Lupus Erythematosus and Rheumatoid Arthritis in a Chinese Han Population.

Authors:  Qi Huang; Wang-Dong Xu; Lin-Chong Su; Xiao-Yan Liu; An-Fang Huang
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.